JILIN PROVINCE XIDIAN PHARMACEUTICAL SCI-TECH DEVELOPMENT CO.,LTD Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd Share Price
Equities
301130
CNE1000058C4
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.62 CNY | +0.37% |
|
+5.53% | -11.69% |
| Sales 2022 | 255M 35.26M 2.94B | Sales 2023 | 225M 31.12M 2.59B | Capitalization | 2.25B 311M 25.92B |
|---|---|---|---|---|---|
| Net income 2022 | 40M 5.52M 460M | Net income 2023 | 50M 6.9M 575M | EV / Sales 2022 | 6.72 x |
| Net cash position 2022 | 616M 85.02M 7.09B | Net cash position 2023 | 547M 75.5M 6.3B | EV / Sales 2023 | 7.56 x |
| P/E ratio 2022 |
54.9
x | P/E ratio 2023 |
44.6
x | Employees | 274 |
| Yield 2022 |
0.55% | Yield 2023 |
-
| Free-Float | 39.41% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.37% | ||
| 1 week | +5.53% | ||
| Current month | +2.54% | ||
| 1 month | +3.88% | ||
| 3 months | +1.53% | ||
| 6 months | -13.06% | ||
| Current year | -11.69% |
1 week
22.83
24.86
1 month
22.4525.00
Current year
15.2028.61
1 year
15.2036.00
3 years
15.2089.90
5 years
15.2089.90
10 years
15.2089.90
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Zhang
CEO | Chief Executive Officer | 68 | 20/21/20 |
Si Meng
DFI | Director of Finance/CFO | 37 | 03/23/03 |
Li Bo Wang
BRD | Director/Board Member | 59 | 20/01/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiang Jun Lu
BRD | Director/Board Member | 56 | 03/23/03 |
Yong Hong Meng
BRD | Director/Board Member | 64 | 20/01/20 |
Ying Xiu Shi
BRD | Director/Board Member | 63 | 20/01/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 24.62 | +0.37% | 796,128 |
| 25/24/25 | 24.53 | +2.76% | 1,276,860 |
| 24/24/24 | 23.87 | -0.29% | 696,628 |
| 23/24/23 | 23.94 | -2.09% | 1,080,063 |
| 22/24/22 | 24.45 | +4.80% | 971,710 |
End-of-day quote Shenzhen S.E., April 26, 2024
More quotes
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd is a China-based company mainly engaged in the research and development (R&D), production and sales of chemical active pharmaceutical ingredients (APIs) and preparations. The Company's products cover the fields of anti anemia drugs, drugs for the treatment of mental disorders and the production of APIs, such as compound ferrous sulfate folic acid tablets, risperidone orally disintegrating tablets, escitalopram oxalate tablets, daphnetin capsules, sodium ferulate and ferrous fumarate.
Sector
Pharmaceuticals
Calendar
24/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -11.69% | 275M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 301130 Stock
